# of Displayed Technologies: 7 / 7

Applied Category Filter (Click To Remove): Cardiovascular & Circulatory


Categories

Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
  • College: College of Medicine (COM)
  • Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
  • Licensing Officer: Willson, Christopher

Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart. The Need In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
  • College: College of Medicine (COM)
  • Inventors: Lewandowski, E. Douglas; Carley, Andrew
  • Licensing Officer: Willson, Christopher

Treating Obesity and Cardiovascular Disease Via Genetic Manipulation of Skin Tissue
TS-062096 — Using tissue nano-transfection to regulate BAT and increase 12,13-diHOME production to treat obesity, cardiovascular disease and type 2 diabetes.
Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all adults in the US. CVD encompasses a number of conditions that affect the heart and vasculature. CVD can arise in response to multiple factors, including obesity. Obesity elevates the…
  • College: College of Medicine (COM)
  • Inventors: Stanford, Kristin; Gallego Perez, Daniel; Ziolo, Mark
  • Licensing Officer: Willson, Christopher

Diagnostic for Early Detection of Heart Damage
TS-059578 — A novel biomarker for the early identification of cardiac damage, including chemotherapy-induced cardiotoxicity.
Despite significant medical advances and technologies, cardiovascular disease remains the number one cause of death in the United States, irrespective of gender or race, resulting in more than 600,000 annual deaths. Additionally, while cancer survivorship has increased significantly, the number one …
  • College: College of Medicine (COM)
  • Inventors: Smith, Sakima; Dib, Patrick; McElroy, Craig
  • Licensing Officer: Schultz, Teri

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Perivascular Drug Delivery Nanoplatform for Preventing Restenosis After Open Surgery
TS-039004 — Pericelle: a nanoparticle based perivascular drug delivery system to prevent stenosis and failure in vascular reconstruction surgeries.
Imaging and re-intervention procedures, necessary to maintain open blood vessels following vascular reconstruction surgery, are expensive. For example, the cost of maintenance for an arteriovenous (AV) fistula used in hemodialysis access has been estimated at $15,000/year. In bypass and AV fistula…
  • College: College of Medicine (COM)
  • Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Shi, Xudong
  • Licensing Officer: Taysavang, Panya

Biomimetic Nanoplatform to Deliver Anti-Restenotic Therapeutics
TS-036654 — A stent-free delivery platform for reducing arterial plaques.
Cardiovascular disease is the leading cause of death in the United States, resulting in more than 600,000 deaths and a significant contributor to overall healthcare costs. Over 28 million Americans are diagnosed with heart disease and contribute more than $30 billion in healthcare-related expenses. …
  • College: College of Medicine (COM)
  • Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Urabe, Go; Wang, Bowen
  • Licensing Officer: Taysavang, Panya

Loading icon